“Cholangiocarcinoma Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cholangiocarcinoma Market.
The Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights about companies that are developing therapies for the treatment of Cholangiocarcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Cholangiocarcinoma Treatment.
Cholangiocarcinoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Cholangiocarcinoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Major Update from ESMO 2022 in the Cholangiocarcinoma Therapeutics Segment:
Relay Therapeutics presented the Late-Breaking Data at the ESMO Congress 2022 demonstrate the potential of RLY-4008 to transform treatment options for Cholangiocarcinoma Patients with FGFR2-Driven Disease.
DelveInsight’s Report covers around 70+ products under different phases of clinical development like –
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Download the sample PDF: https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight
Cholangiocarcinoma Therapeutics Market Assessment:
There are approx. 70+ key companies which are developing therapies for Cholangiocarcinoma. Currently, ImmunoGen has its Cholangiocarcinoma drug candidates in the most advanced stage of clinical development.
Major Players in Cholangiocarcinoma Therapeutics Market include:
QED Therapeutics, Taiho Oncology, Merck Sharp & Dohme Corp., EMD Serono/Merck, Eisai Inc., 3D Medicines, PCI Biotech AS, Basilea Pharmaceutica, Newish Technology (Beijing) Co., Ltd., Bristol-Myers Squibb, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, AstraZeneca, Janssen Pharmaceuticals, Syndax Pharmaceuticals, Servier, CSPC Ouyi Pharmaceutical Co., Ltd., Eli Lilly and company, Elevation oncology, Senhwa Biosciences, Immunitor LLC, Chia Tai Tianqing Pharmaceutical, InnoCare Pharma, Genoscience Pharma, PureTech, Intensity therapeutics, Forma Therapeutics, TCR2 therapeutics, Elucida Oncology, NGM Biopharmaceuticals, Cellestia Biotech, Klus Pharma, PCI Biotech AS, Sirnaomics, Relay Therapeutics, Bold Therapeutics, Leap therapeutics, Boehringer Ingelheim, Elicio Therapeutics, Ad many others
Cholangiocarcinoma Emerging Drugs
• TAS-120: Taiho Oncology
• Pembrolizumab: Merck Sharp & Dohme
• E7090: Eisai
And many more
Further product details are provided in the report. Download the sample report to understand more about the key companies and emerging therapies:
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Cholangiocarcinoma Current Treatment Patterns
4. Cholangiocarcinoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cholangiocarcinoma Late Stage Products (Phase-III)
7. Cholangiocarcinoma Mid-Stage Products (Phase-II)
8. Cholangiocarcinoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cholangiocarcinoma Discontinued Products
13. Cholangiocarcinoma Product Profiles
14. Key Companies in the Cholangiocarcinoma Market
15. Key Products in the Cholangiocarcinoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Cholangiocarcinoma Unmet Needs
18. Cholangiocarcinoma Future Perspectives
19. Cholangiocarcinoma Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Antibody-mediated Rejection Market
“Antibody-mediated Rejection Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Antibody-mediated Rejection Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States